SLC38A2 and pancreatic neoplasm: Notably, SLC38A2/SNAT2 was identified to be the main concentrative alanine transporter utilized by pancreatic cancer cells and targeting SLC38A2 was sufficient to suppress alanine uptake by pancreatic cancer cells and cause significant re-wiring of compartmentalized pyruvate metabolism [60].